All In Biotech

Drug Trial Radar · NCT06369285

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

A Phase 2 Study of Alisertib in Combination With Endocrine Therapy in Patients With HR+, HER2-negative Recurrent or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Nov 19, 2024

Primary completion

Dec 30, 2027

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Puma Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy. Participants randomized prior to Amendment 4 are randomized 1:1:1 to Arm 1, Arm 2 or Arm 3. Participants randomized under Amendment 4 will be randomized 1:1 to Arm 1 or Arm 2.

Conditions

  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Metastatic Breast Cancer
  • Recurrent Breast Cancer

Interventions

  • AlisertibDrug

    Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.

  • Endocrine therapyDrug

    Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information. 1 mg of anastrozole tablet by mouth once daily or 2.5 mg of letrozole tablet by mouth once daily or 25 mg of exemestane tablet by mouth once daily or 20 mg of tamoxifen tablet by mouth once daily or 500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Within Dose SubgroupTime frame: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
  2. Duration of Response (DOR) Within Dose SubgroupTime frame: From start date of response (after date of randomization) to first PD, assessed up to 48 months
  3. Disease Control Rate (DCR) Within Dose SubgroupTime frame: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
  4. Progression Free Survival (PFS) Within Dose SubgroupTime frame: From date of randomization to date of recurrence, progression or death, assessed up to 48 months
  5. Overall Survival (OS) Within Dose SubgroupTime frame: From date of randomization to death, assessed up to 48 months
  6. Percentage of Participants With Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) in the Enrolled PopulationTime frame: From date of first dose through last dose plus 28 days, assessed up to 48 months

Locations

53 sites in 3 countries. Site status is shown where the registry gives one.

  • Alabama Oncology

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Hospital

    Phoenix, Arizona · Recruiting

  • Beverly Hills Cancer Center

    Beverly Hills, California · Recruiting

  • MemorialCare Orange Coast Medical Center

    Fountain Valley, California · Recruiting

  • City of Hope at Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • LA Cancer Network

    Los Angeles, California · Recruiting

  • UCLA Department of Medicine - Hematology/Oncology

    Los Angeles, California · Recruiting

  • University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • University of Colorado School of Medicine

    Aurora, Colorado · Recruiting

  • Yale University, Yale Cancer Center

    New Haven, Connecticut · Withdrawn

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Cancer Specialists of North Florida

    Jacksonville, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • University of Illinois Cancer Center

    Chicago, Illinois · Recruiting

  • The University of Chicago

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Minnesota, Masonic Cancer Center

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Missouri Cancer Associates

    Columbia, Missouri · Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri · Recruiting

  • Oncology Hematology Associates

    Springfield, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Cancer Care Specialists

    Reno, Nevada · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • UNC Hospitals, University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • The Ohio State University, Stefanie Spielman Comprehensive Breast Center

    Columbus, Ohio · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • Alliance Cancer Specialists

    Horsham, Pennsylvania · Recruiting

  • University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh (UPMC)

    Pittsburgh, Pennsylvania · Recruiting

  • Tennessee Oncology, Greco-Hainsworth Center for Research

    Nashville, Tennessee · Recruiting

  • Texas Oncology

    Dallas, Texas · Recruiting

  • Virginia Cancer Institute

    Richmond, Virginia · Recruiting

  • Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa)

    Lisbon, Portugal · Recruiting

  • Fundação Champalimaud

    Lisbon, Portugal · Recruiting

  • Hospital CUF Descobertas

    Lisbon, Portugal · Recruiting

  • Instituto Português Oncologia Do Porto

    Porto, Portugal · Recruiting

  • Hospital General Universitario Dr. Balmis

    Alicante, Spain · Recruiting

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.